Point Roberts, WA (Investorideas.com Newswire) September 3, 2010- InvestorIdeas.com, leader in sector research for investors, reports on recent Healthcare Technology Stocks news and trading for September 3rd.

Healthcare Technology Stocks include Healthmed Services Ltd. (OTCBB: HEME), Cytta Corp. (OTCBB: CYCA), Healthstream Inc.  (NASDAQ:HSTM), A.D.A.M. Inc. (NGM: ADAM) and Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)

Sector Snapshot: Trading at time or release

Allscripts (NASDAQ:MDRX ) trading at $17.59 USD, up 0.25 (1.44%)

A.D.A.M. Inc. (NGM: ADAM) trading at $ 5.50, up 0.03 (0.55%)

Cytta Corp. (OTCBB: CYCA) trading at 0.0017 - 0.0018

BSD Medical Receives FDA 510(k) Clearance to Market the MicroThermX Microwave Ablation System

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market its MicroThermX Microwave Ablation System (MTX-180) for ablation of soft tissue. Clearance from the FDA of BSD’s 510(k) Premarket Notification submission authorizes the commercial sale of the MTX-180 in the United States. The MTX-180 was designed to provide a higher power, optimized system targeted to the growing therapeutic interventional and surgical oncology market.

The MTX-180 utilizes innovative synchronous phased array technology that was developed and patented by BSD to deliver targeted microwave energy to ablate (destroy) soft tissue. BSD employed its extensive 32-year background in developing thermal therapy systems in the design of the MTX-180.

Medtronic Signs Agreement to Acquire Osteotech

Medtronic Inc., (NYSE: MDT) and Osteotech, Inc., (Nasdaq: OSTE) today announced that the companies have signed a definitive agreement under which Medtronic will acquire Osteotech for $6.50 per share in cash for each share of Osteotech common stock. The total value of the transaction is expected to be approximately $123 million.

Osteotech is a leader in the growing field of biologic products for regenerative healing, and has pioneered several innovative technology platforms including Grafton® demineralized bone matrix, a family of products which has a large and growing body of evidence supporting its best-in-class bone generating capabilities. Osteotech's differentiated portfolio of biologics also includes MagniFuse(TM) Bone Grafts and Plexur® Biocomposites, which are utilized in a broad range of musculoskeletal surgical procedures. In addition, Osteotech is in the midst of seeking U.S. Food & Drug Administration clearance for the first product based upon its first-in-class HCT(TM) (Human Collagen Technology) platform, an engineered human collagen biomaterial.

NeoStem to Receive $700,000 from the U.S. Army's Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic

NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that it has been awarded a $700,000 contract from the U.S. Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center (USAMRMC-TATRC) under U.S. Army Medical Research Acquisition Activity contract number: (W81XWH-10-2-0039). This contract is for the purpose of evaluating the use of topically applied bone marrow-derived adult mesenchymal stem cells (MSCs) for rapid wound healing. The Company previously announced that this funding was included in the Department of Defense FY09 Appropriations Bill and will begin receiving funds to initiate the program in 2010.